Nintedanib in Patients With Autoimmune Disease–Related Progressive Fibrosing Interstitial Lung Diseases: Subgroup Analysis of the INBUILD Trial

To analyze the efficacy and safety of nintedanib in patients with fibrosing autoimmune disease–related interstitial lung diseases (ILDs) with a progressive phenotype.

[1]  S. Walsh,et al.  Nintedanib in progressive interstitial lung diseases: data from the whole INBUILD trial , 2021, European Respiratory Journal.

[2]  L. Richeldi,et al.  Nintedanib and immunomodulatory therapies in progressive fibrosing interstitial lung diseases , 2021, Respiratory Research.

[3]  J. Goldin,et al.  Tocilizumab Prevents Progression of Early Systemic Sclerosis–Associated Interstitial Lung Disease , 2021, Arthritis & rheumatology.

[4]  L. Czirják,et al.  Progressive interstitial lung disease in patients with systemic sclerosis-associated interstitial lung disease in the EUSTAR database , 2020, Annals of the Rheumatic Diseases.

[5]  T. Maher,et al.  Safety and tolerability of nintedanib in patients with systemic sclerosis-associated interstitial lung disease: data from the SENSCIS trial , 2020, Annals of the Rheumatic Diseases.

[6]  M. Roth,et al.  Treatment With Mycophenolate and Cyclophosphamide Leads to Clinically Meaningful Improvements in Patient‐Reported Outcomes in Scleroderma Lung Disease: Results of Scleroderma Lung Study II , 2020, ACR open rheumatology.

[7]  R. Bloigu,et al.  Prognosis and causes of death of patients with acute exacerbation of fibrosing interstitial lung diseases , 2020, BMJ Open Respiratory Research.

[8]  K. Michaud,et al.  Impact of the pattern of interstitial lung disease on mortality in rheumatoid arthritis: A systematic literature review and meta-analysis. , 2019, Seminars in Arthritis & Rheumatism.

[9]  Ø. Molberg,et al.  Tracking Impact of Interstitial Lung Disease in Systemic Sclerosis in a Complete Nationwide Cohort. , 2019, American journal of respiratory and critical care medicine.

[10]  J. Belperio,et al.  Endotype–phenotyping may predict a treatment response in progressive fibrosing interstitial lung disease , 2019, EBioMedicine.

[11]  T. Johkoh,et al.  Prognostic factors for primary Sjögren's syndrome-associated interstitial lung diseases. , 2019, Respiratory medicine.

[12]  S. Walsh,et al.  Nintedanib in Progressive Fibrosing Interstitial Lung Diseases. , 2019, The New England journal of medicine.

[13]  D. Riches,et al.  Potential of nintedanib in treatment of progressive fibrosing interstitial lung diseases , 2019, European Respiratory Journal.

[14]  G. Raghu,et al.  Nintedanib for Systemic Sclerosis-Associated Interstitial Lung Disease. , 2019, The New England journal of medicine.

[15]  Jonathan H. Chung,et al.  Computed Tomography Honeycombing Identifies a Progressive Fibrotic Phenotype with Increased Mortality across Diverse Interstitial Lung Diseases , 2019, Annals of the American Thoracic Society.

[16]  C. Denton,et al.  Rationale for the evaluation of nintedanib as a treatment for systemic sclerosis–associated interstitial lung disease , 2019, Journal of scleroderma and related disorders.

[17]  S. Cerri,et al.  Acute exacerbation of interstitial lung diseases secondary to systemic rheumatic diseases: a prospective study and review of the literature. , 2019, Journal of thoracic disease.

[18]  M. Kolb,et al.  The natural history of progressive fibrosing interstitial lung diseases , 2019, Respiratory Research.

[19]  J. Murchison,et al.  Predicting outcomes in rheumatoid arthritis related interstitial lung disease , 2018, European Respiratory Journal.

[20]  J. Corander,et al.  Progression and mortality of interstitial lung disease in mixed connective tissue disease: a long-term observational nationwide cohort study , 2018, Rheumatology.

[21]  Jonathan H. Chung,et al.  Phenotypic Clusters Predict Outcomes in a Longitudinal Interstitial Lung Disease Cohort , 2017, Chest.

[22]  C. Maier,et al.  Nintedanib inhibits macrophage activation and ameliorates vascular and fibrotic manifestations in the Fra2 mouse model of systemic sclerosis , 2017, Annals of the rheumatic diseases.

[23]  E. Matteson,et al.  Progressive Decline of Lung Function in Rheumatoid Arthritis–Associated Interstitial Lung Disease , 2017, Arthritis & rheumatology.

[24]  Jonathan H. Chung,et al.  Predictors of mortality in rheumatoid arthritis-associated interstitial lung disease , 2015, European Respiratory Journal.

[25]  G. Schett,et al.  Nintedanib inhibits fibroblast activation and ameliorates fibrosis in preclinical models of systemic sclerosis , 2015, Annals of the rheumatic diseases.

[26]  Alexander Pautsch,et al.  Mode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis , 2015, European Respiratory Journal.

[27]  Anand Devaraj,et al.  Connective tissue disease related fibrotic lung disease: high resolution computed tomographic and pulmonary function indices as prognostic determinants , 2013, Thorax.

[28]  T. Colby,et al.  Acute exacerbation in rheumatoid arthritis-associated interstitial lung disease: a retrospective case control study , 2013, BMJ Open.

[29]  S. Birring,et al.  The development and validation of the King's Brief Interstitial Lung Disease (K-BILD) health status questionnaire , 2012, Thorax.

[30]  G. Mynarek,et al.  Prevalence and severity of interstitial lung disease in mixed connective tissue disease: a nationwide, cross-sectional study , 2012, Annals of the rheumatic diseases.

[31]  Cynthia S Crowson,et al.  Incidence and mortality of interstitial lung disease in rheumatoid arthritis: a population-based study. , 2010, Arthritis and rheumatism.

[32]  Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis. , 2015, The New England journal of medicine.